BioLife Solutions, Inc., a developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract aseptic media manufacturer, announced that Robert Preti, Ph.D., President and Chief Scientific Officer of Progenitor Cell Therapy, a subsidiary of NeoStem, Inc, has joined its Scientific Advisory Board (SAB).
According to a release, Dr. Preti co-founded Progenitor Cell Therapy (PCT) in 1999. Since its inception, PCT has served over 100 clients from around the world and has experience with more than 20 different cell-based therapeutics. PCT has performed over 30,000 cell therapy procedures in its cell therapy manufacturing facilities, and processed and stored over 18,000 cell therapy products (including approximately 7,000 umbilical cord blood units, 10,000 blood and marrow derived stem cell units and 1,000 dendritic cell units) and arranged the logistics and transportation for over 14,000 cell therapy products for clinical use by over 5,000 patients.
Mike Rice, BioLife Solutions President and CEO, commented on the announcement by stating, "Bob Preti is one of the most experienced and respected clinicians and corporate executives in the worldwide clinical cell therapy and regenerative medicine markets. We are honored that he has accepted our invitation to join our esteemed SAB. BioLife and PCT have several mutual customers and we look forward to future SAB collaborative discussions on how our best in class biopreservation media products can further improve biopreservation outcomes for commercial and non-profit clinical organizations."
BioLife Solutions noted that TriMarkPublications.com cites in its newly published "Regenerative Medicine Markets" report that the regenerative medicine market will catapult to over $35 billion by 2019.
Dr. Preti remarked on his joining BioLife's SAB by stating, "I have known of and seen the quality and performance of BioLife's serum-free, protein-free cGMP biopreservation media products for many years. I have also collaborated on many occasions with its management team and have been extremely impressed by the corporate culture and customer focus of BioLife. I look forward to joining BioLife's exceptional scientific advisory board."
Additionally, BioLife's Scientific Advisory Board is chaired by Aby J. Mathew, Ph.D., Senior Vice President and Chief Technology Officer at BioLife and is comprised of the following members:
-Scott M. Burger, M.D., principal of Advanced Cell and Gene Therapy, a consulting firm specializing in cell, gene, and tissue- based therapies.
-Lizabeth J. Cardwell, MT (ASCP), MBA, RAC, Compliance Consulting for Cell Therapy and Biotechnology. Cardwell has provided Quality Assurance and Regulatory consulting for start-up cell therapy and biotechnology companies since 2005. Prior to August 2005, Cardwell held the position of Director of Regulatory Affairs and Quality Assurance at Xcyte Therapies.